Don't let these struggling companies shatter your investment portfolio.
News & Analysis: Eastman Kodak
While these companies look like bargains, the level of unnecessary risk is the reason they're dirt cheap.
The company's new coronavirus-focused pharmaceutical business could fail to receive the funding it needs.
There was a big division across the broader market.
Kodak's seminal loan agreement may now be in serious jeopardy. Here's why.
President Trump's executive order could provide a boost for the company's fledgling pharmaceutical business.
Strong trading before the official announcement of a $765 million loan spurred the Securities and Exchange Commission to investigate.
A surprising pivot made the struggling photography company one of the hottest stocks on the market.
The film and digital imaging specialist has turned a new leaf, but can it succeed?
Reports of an SEC investigation have investors on edge.